Authorizes coverage of prescriptive hormone replacement therapy.
This bill requires certain health coverage arrangements in New Jersey to cover a 12-month refill of prescription hormone replacement therapy when the medication does not require refrigeration. The requirement applies to private health benefits plans, plans purchased by the State Health Benefits Commission and the School Employees’ Health Benefits Commission, and the Medicaid program. If the hormone therapy is a controlled dangerous substance, the bill instead requires coverage of the maximum refill allowed under state and federal law at one time.
The bill defines “prescription hormone replacement therapy” broadly as FDA-approved drugs used to medically suppress, increase, or replace hormones the body is not producing at intended levels, while expressly excluding GLP-1 drugs and GLP-1 receptor agonists. It also allows limited exceptions: plans may restrict refills in the last quarter of the plan year if a full 12-month supply has already been dispensed, and providers may temporarily limit refills to a 90-day supply during an acute dispensing shortage until supply stabilizes. The bill permits drug utilization management strategies to the extent otherwise allowed by law.
The bill would amend the state’s health insurance and Medicaid coverage rules by creating a new mandate for extended refills of hormone replacement therapy. It would affect carrier health plans, the State Health Benefits Program, the School Employees’ Health Benefits Program, and Medicaid, requiring them to cover larger refill quantities for qualifying medications and, in Medicaid, to do so without cost-sharing for 12-month refills of non-refrigerated therapy. The measure would take effect immediately and apply to plans and contracts issued or renewed on or after enactment.
Based on the bill text and the absence of recorded committee testimony or votes, the overall sentiment appears supportive and policy-driven, with the bill framed as a coverage expansion and access measure. The structure of the bill suggests an intent to reduce refill barriers and improve continuity of treatment for patients using hormone replacement therapy. No recorded opposition, amendments, or vote history is available in the provided materials.
The main points of potential contention are likely to be cost, utilization control, and the scope of the mandate. Insurers and public purchasers may be concerned about increased pharmacy spending and reduced flexibility in refill management, while the bill preserves some utilization management authority and shortage-based refill limits to address those concerns. Another notable drafting choice is the explicit exclusion of GLP-1 drugs and GLP-1 receptor agonists, which narrows the bill’s scope and may reflect an effort to avoid extending the refill mandate to weight-loss or diabetes medications that have generated separate policy debates.